Mike R. Russell

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
Mike R Russell
Publication record
28 papers · 1,377 citations · H-index 13

PAPERS

The functional variant rs34330 of CDKN1B is associated with risk of neuroblastoma
201758 citationsauthor #6
Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma
201677 citationsauthor #5
Abstract 5040: Genomic and proteomic characterization of anti-androgen resistant cell lines
20160 citationsauthor #2
Abstract 4305: NMI as a biomarker of response to CDK4/6 inhibition in a preclinical model of neuroblastoma
20150 citationsauthor #4
Abstract B34: Antitumor activity and sensitivity evaluation of novel BET inhibitors in neuroblastoma
20150 citationsauthor #6
Abstract 144: CASC15 is a tumor suppressor lncRNA at the 6p22 neuroblastoma susceptibility locus
20150 citationsauthor #1
CASC15-S Is a Tumor Suppressor lncRNA at the 6p22 Neuroblastoma Susceptibility Locus.
2015147 citationsauthor #1
Abstract 5237: The long intergenic noncoding RNA LINC00340 is a neuroblastoma susceptibility gene
20142 citationsauthor #1
Rare variants in TP53 and susceptibility to neuroblastoma.
2014106 citationsauthor #7
Abstract 2744: CDK4/CDK6 inhibition is potently active in a definable subset of human neuroblastomas.
20134 citationsauthor #3
Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma
2013357 citationsauthor #2
Molecular and Cellular Pathobiology Interleukin-1 b Promotes Skeletal Colonization and Progression of Metastatic Prostate Cancer Cells with Neuroendocrine Features
201359 citationsauthor #2
Cancer Therapy : Preclinical Dual CDK 4 / CDK 6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma
20131 citationsauthor #2
Combination therapy targeting the Chk1 and Wee1 kinases shows therapeutic efficacy in neuroblastoma.
2013120 citationsauthor #1
COMBINATION THERAPY TARGETING THE CHK1 AND WEE1 KINASES DEMONSTRATES THERAPEUTIC EFFICACY IN NEUROBLASTOMA
20124 citationsauthor #1
Abstract 1436: Therapeutic targeting of the DNA damage mediators CHK1 and Wee1 in neuroblastoma
20121 citationsauthor #1
RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma
2011257 citationsauthor #5
Abstract 4758: Inhibition of checkpoint kinase 1 (Chk1) as a potential therapeutic for pediatric neuroblastoma
20118 citationsauthor #1
Tumor and Stem Cell Biology Cancer Research The α-Receptor for Platelet-Derived Growth Factor Confers Bone-Metastatic Potential to Prostate Cancer Cells by Ligand-and Dimerization-Independent Mechanisms
201013 citationsauthor #1
The α -Receptor for Platelet-Derived Growth Factor Confers Bone-Metastatic Potential to Prostate Cancer Cells by Ligand- and Dimerization-Independent Mechanisms
20103 citationsauthor #1
Targeting the α Receptor for Platelet-Derived Growth Factor as a Primary or Combination Therapy in a Preclinical Model of Prostate Cancer Skeletal Metastasis
201047 citationsauthor #1
Abstract 1468: Antagonism of platelet-derived growth factor receptor-α as a potential therapeutic for prostate cancer bone metastases
20100 citationsauthor #1
Microenvironment Factors Influencing Skeletal Metastases
20100 citationsauthor #5
The alpha-receptor for platelet-derived growth factor confers bone-metastatic potential to prostate cancer cells by ligand- and dimerization-independent mechanisms.
201010 citationsauthor #1
The α-receptor for platelet-derived growth factor as a target for antibody-mediated inhibition of skeletal metastases from prostate cancer cells
200942 citationsauthor #1
Role of the interactions between the chemokine CX3CL1/fractalkine and its receptor CX3CR1 in cell-adhesion and extravasation during the early arrival of circulating cancer cells to the skeleton.
20080 citationsauthor #2
Human bone marrow activates the Akt pathway in metastatic prostate cells through transactivation of the alpha-platelet-derived growth factor receptor.
200722 citationsauthor #2
Human Bone Marrow Activates the Akt Pathway in Metastatic Prostate Cells through Transactivation of the α-Platelet–Derived Growth Factor Receptor
200736 citationsauthor #2

TIMELINE

2007 58 citations

2008 0 citations

2009 42 citations

2010 73 citations

2011 265 citations

2012 5 citations

2013 541 citations

2014 108 citations

2015 147 citations

2016 77 citations

2017 58 citations

Mike R. Russell

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT